Through the first nine months of 2025, AbbVie reported revenue of $44.5 billion, an 8% increase year-over-year, driven by strong sales from its immunology portfolio. Adjusted earnings per share stood at $7.29, modestly down from $7.96 due to one-time acquisition charges. Management’s long-term guidance, issued in early 2024, projects high single-digit annual revenue growth through 2029, underscoring confidence in the company’s ability to sustain momentum over the next five years.

AbbVie has raised its combined 2027 sales forecast for Skyrizi and Rinvoq by $4 billion above the initial $27 billion target, reflecting exceptional uptake in immunology indications. Oncology revenues are expected to resume growth in 2026, while newer launches—including the schizophrenia treatment Vraylar and migraine therapy Qulipta—should contribute incremental gains. Humira, despite losing patent exclusivity in 2023, still generated $3.3 billion through nine months, down 55% year-over-year, but is projected to continue its gradual decline without materially impacting long-term guidance.

AbbVie trades at 16.1 times forward earnings versus a healthcare sector average of 18.2, suggesting reasonable valuation support. Its price/earnings-to-growth ratio stands at 0.4, well below the threshold for undervaluation. The company also boasts 54 consecutive years of dividend increases, a forward yield of 3%, and a cash payout ratio of 61.8%, reinforcing its status as a Dividend King. These factors combine to position AbbVie as a strong buy candidate heading into 2026.